These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11789394)

  • 1. [Pharma-clinics medication of the month. Nebivolol (Nobiten)].
    Scheen AJ
    Rev Med Liege; 2001 Nov; 56(11):788-91. PubMed ID: 11789394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol in the management of essential hypertension: a review.
    McNeely W; Goa KL
    Drugs; 1999 Apr; 57(4):633-51. PubMed ID: 10235696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
    Lindamood C; Ortiz S; Shaw A; Rackley R; Gorski JC
    J Clin Pharmacol; 2011 Apr; 51(4):575-85. PubMed ID: 20489028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol: a new antihypertensive agent.
    Gray CL; Ndefo UA
    Am J Health Syst Pharm; 2008 Jun; 65(12):1125-33. PubMed ID: 18541682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nebivolol treatment in essential arterial hypertension].
    Ghiuru R; Rezuş C; Ambăruş V; Ionescu S; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):756-9. PubMed ID: 12092233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V
    Am J Cardiol; 2009 Jan; 103(2):273-8. PubMed ID: 19121451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients.
    Marazzi G; Volterrani M; Caminiti G; Iaia L; Cacciotti L; Massaro R; Sposato B; Vitale C; Mercuro G; Rosano G
    Adv Ther; 2010 Sep; 27(9):655-64. PubMed ID: 20690006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
    Zanchetti A
    Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A; Nuzum DS; Jolly JL
    Ann Pharmacother; 2006; 40(7-8):1353-60. PubMed ID: 16822893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension].
    Zadionchenko VS; Sandomirskaia AP; Adasheva TV; Gorbacheva EV; Matveev DV; Mareeva AP; Buval'tsev VI
    Kardiologiia; 2002; 42(5):14-8. PubMed ID: 12494141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol for the treatment of heart failure.
    Dery AS; Hamilton LA; Starr JA
    Am J Health Syst Pharm; 2011 May; 68(10):879-86. PubMed ID: 21546638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide mediated venodilator effects of nebivolol.
    Bowman AJ; Chen CP; Ford GA
    Br J Clin Pharmacol; 1994 Sep; 38(3):199-204. PubMed ID: 7826820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease.
    Howlett JG
    Can J Cardiol; 2014 May; 30(5 Suppl):S29-37. PubMed ID: 24750980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.